← All indications
Immunization
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Subtype terms (5)
More specific conditions that are subtypes of Immunization in the MeSH hierarchy.
- Immunization, Passive
- Immunization Schedule
- Immunization, Secondary
2 drugs approved
- Immunotherapy, Active
3 drugs (2 approved, 1 experimental)
- Vaccination
41 drugs (24 approved, 17 experimental)
Drugs by status
Phase 4 trials (16)
- bacille calmette-guerin
- diphtheria, tetanus and whole cell pertussis vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- multi-valent pneumococcal conjugate vaccine
- acellular pertussis vaccine
- ev71 vaccine
- human papillomavirus 9-valent vaccine, recombinant
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- polio, inactivated poliovirus vaccine
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- technetium tc-99m pentetate kit
- bnt162b2
- Inactivated polio virus - Enhanced
Phase 3 trials (4)
Phase 2 trials (13)
- 23-valent pneumococcal polysaccharide vaccine
- ibuprofen
- inactivated rabies vaccine
- acetaminophen
- serogroup b meningococcal vaccine
- syn023
- yellow fever vaccine 17d strain
- inactivated influenza vaccine
- wrss2
- human rotavirus, live attenuated
- meningococcal groups a, b, c, w, and Y vaccine
- chulacov19 mrna vaccine
- bivalent bnt162b2
Phase 1 trials (13)